Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials-Reference-Cited by-同舟云学术

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

Published:2015-08 Issue:9993 Volume:386 Page:541-551
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Griffiths Christopher E M,Reich Kristian,Lebwohl Mark,van de Kerkhof Peter,Paul Carle,Menter Alan,Cameron Gregory S,Erickson Janelle,Zhang Lu,Secrest Roberta J,Ball Susan,Braun Daniel K,Osuntokun Olawale O,Heffernan Michael P,Nickoloff Brian J,Papp Kim

Publisher

Elsevier BV

Subject

General Medicine

Reference36 articles.

1. Psoriasis;Di Meglio;Cold Spring Harb Perspect Med,2014

2. Immunology of psoriasis;Lowes;Annu Rev Immunol,2014

3. Psoriasis causes as much disability as other major medical diseases;Rapp;J Am Acad Dermatol,1999

4. Living with psoriasis: prevalence of shame, anger, worry, and problems in daily activities and social life;Sampogna;Acta Derm Venereol,2012

5. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening;Kimball;J Am Acad Dermatol,2008

Cited by 732 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Shared Pathophysiology of Inflammatory Bowel Disease and Psoriasis: Unraveling the Connection;Cureus;2024-09-03

2. Quality of reporting and concordance between sources of adverse events in the treatment of moderate-to-severe psoriasis: a cross-sectional study of RCTs from a Cochrane systematic review;Journal of Clinical Epidemiology;2024-09

3. Treatment strategies for Spondyloarthritis: Implementation of precision medicine – Or “one size fits all” concept?;Autoimmunity Reviews;2024-09

4. IL-17 and IL-23 Inhibitors Have the Fastest Time to Meaningful Clinical Response for Plaque Psoriasis: A Network Meta-Analysis;Journal of Clinical Medicine;2024-08-29

5. Injection site reactions resulting from the use of biological therapy in the treatment of moderate-to-severe plaque psoriasis;Expert Opinion on Drug Safety;2024-08-17